GALENEA

Galenea Corp., a biopharmaceutical company, engages in developing therapeutics for central nervous system (CNS) diseases. The company focuses on psychiatric disorders, schizophrenia and calcineurin, and obesity and 5-HT2C agonists. Its products include in vitro and in vivo synaptic functional screening and brain slice electrophysiology assays, which include techniques for recording disease-relevant neuronal activity in the prefrontal cortex to measure the effects of drug candidates in animals performing critical memory or cognition-dependent tasks. The company was founded in 2003 and is based in Cambridge, Massachusetts.